US 10,376,530 B2 · Pharmaceutical composition for preventing or treating gleevec-resistant leukemia containing ginsenoside F1 or ginsenoside Rg3 as an active ingredient

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating Gleevec-resistant leukemia, containing, as an active ingredient, ginsenoside F1 or Rg3 which exhibits a preventive or therapeutic effect on Gleevec-resistant leukemia through enhancing cell killing activity of NK cells; a method for treating Gleevec-resistant leukemia comprising a step of administering the pharmaceutical composition; and a food composition for preventing or ameliorating Gleevec-resistant leukemia. Since the pharmaceutical composition of the present invention can effectively treat leukemia that exhibits resistance to conventional Gleevec, the pharmaceutical composition can be widely used for effective leukemia treatment.

Claims2

Dependent claims

A method for treating imatinib-resistant leukemia comprising administering a composition comprising ginsenoside F1 or a pharmaceutically acceptable salt thereof as the only active ingredient to a subject having or at risk of developing imatinib-resistant leukemia, wherein the leukemia is chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL), wherein ginsenoside F1 improves the cell-killing activity of natural killer cells.

Dependencies are inferred from the claim text.

Facts

Application

15/511,637Filed 4 May 2016

Priority

KR 10-2015-00633906 May 2015

Published

US 2018/0071327 A115 Mar 2018

Granted

13 Aug 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61K 31/704
Attached to a carbocyclic compound, e.g. phloridzin: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin,…
A23L 33/125
Using additives: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings
A61K 31/70
Medicinal preparations containing organic active ingredients: carbohydrates; Sugars; Derivatives thereof

Pharmaceutical composition for preventing or treating gleevec-resistant leukemia containing ginsenoside F1 or ginsenoside Rg3 as an active ingredient

Life of this patent

Pharmaceutical composition for preventing or treating gleevec-resistant leukemia containing ginsenoside F1 or ginsenoside Rg3 as an active ingredient

Life of this patent

Abstract

Claims2